Skip to main content

Notice of Special Interest (NOSI): Technology Development for Cancer Control and Population Science Research


The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field.

Background

NCI administers two unique programs focused on the development of technologies that offer transformative potential for advancing cancer research. The Innovative Molecular Analysis Technologies (IMAT) program supports highly innovative, data-generating platforms and methodologies. The program solicits grant applications for early-stage development of novel tools and methods that enable cancer researchers across the entire spectrum of cancer research. The Informatics Technologies for Cancer Research (ITCR) program supports powerful data analysis, management, and visualization technologies. The program supports research-driven informatics technology development spanning all aspects of cancer research and across the tool development lifecycle.

While NCI has been successful in soliciting novel technology development proposals that focus on advancing basic biological research and clinical cancer research, there have been fewer applications received that are specifically aimed at addressing technology gaps that might accelerate research for investigators focused on cancer control and population sciences, including cancer healthcare delivery, surveillance, behavior, epidemiology, and population-scale -omics research.

Application and Submission Information

This notice applies to due dates on or after March 01, 2023 and subsequent receipt dates through the expiration date of this notice.  

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

Activity Code FOA First Available Application Due Date Expiration Date
R61 RFA-CA-23-002 – Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) March 1, 2023 September 1, 2023
R33 RFA-CA-23-003 – Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) March 1, 2023 September 1, 2023
R61 RFA-CA-23-004 – Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) March 1, 2023 September 1, 2023
R33 RFA-CA-23-005 – Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) March 1, 2023 September 1, 2023
R21 RFA-CA-23-014 – Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) June 13, 2023 November 17, 2023
U01 RFA-CA-23-015 – Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) June 13, 2023 November 17, 2023
U24 RFA-CA-23-016 – Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) June 13, 2023 November 17, 2023
U24 RFA-CA-23-017 – Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) June 13, 2023 November 17, 2023